Proteasome inhibitors have reshaped treatment for blood cancers over two decades, with bortezomib earning its first FDA approval in 2003 and carfilzomib and ixazomib following, yet every one of those approvals is confined to hematologic malignancies. SHY Therapeutics is now betting that the confinement is a design flaw, not a biological ceiling. The New York-based company has dosed the first patient in Luca-1, a first-in-human Phase 1 study of SHY-ONC6, an oral small molecule targeting solid tumors through a mechanism no approved proteasome inhibitor currently uses.
The mechanistic distinction matters more than it might seem at first. Efforts to extend proteasome inhibition into solid tumors have faced persistent challenges, and part of that story traces back to where in the proteasome existing drugs strike. Bortezomib, carfilzomib, and ixazomib all inhibit the 20S Core Particle. SHY-ONC6 instead targets the ATPases within the 19S Regulatory Particle, the machinery that unfolds and feeds proteins into the degradation complex. Hitting a structurally and functionally distinct node on the same pathway is a credible argument for a different tolerability and activity profile in solid tumors, even if preclinical promise is no guarantee of clinical translation.
The Luca-1 trial is an open-label, multicenter Phase 1 designed to assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. Initial data are expected in 2027. That timeline is worth noting: a roughly 18-month window from first dose to first readout is a normal pace for a solid tumor dose-escalation study, but it means SHY will be running on preclinical credibility alone for some time before investors or partners can evaluate clinical signal. The company’s broader platform targets ATPases and GTPases across oncology and infectious disease, so Luca-1 is simultaneously a proof-of-concept for SHY-ONC6 and a real-world stress test of the platform’s core hypothesis.
The single number worth tracking as Luca-1 advances is the dose at which SHY-ONC6 achieves pharmacodynamic evidence of 19S inhibition in patients, because that threshold will determine whether the tolerability advantage seen in preclinical solid tumor models is real or an artifact of species differences. Without a confirmed active dose in humans, the mechanistic story remains theoretical.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
